Dhipatimendi rePasi Pose

Musi wa21 Kubvumbi, 2026, Center for Drug Evaluation (CDE) yeNational Medical Products Administration yakazivisa kuti HS-20093 yekubaiwa jekiseni (risvutatug rezetecan) yakasarudzwa semushonga weBreakthrough Therapy wekurapa varwere vane prostate isingapindike...Verenga zvakawanda»

Munguva pfupi yapfuura, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yeChina yakazivisa kuti Encorafenib yakatenderwa kwenguva pfupi kuti iongororwe zvakanyanya. Ichashandiswa pamwe chete necetuximab uye FOLFOX chemotherapy regimen senzira yekutanga yekurapa...Verenga zvakawanda»

Kana mashoko ekuti "kenza yepancreatic" akaonekwa pamushumo wekuongorora chirwere—kunyanya kana achiperekedzwa ne "25 liver metastases"—mhuri dzisingaverengeki dzakawira mukuora mwoyo. Chirwere ichi, chinozivikanwa sa "mambo wekenza," chakamboonekwa kuti chine multiple metastases, kazhinji...Verenga zvakawanda»

Munguva pfupi yapfuura, Bayer yakazivisa kuti National Medical Products Administration (NMPA) yeChina yakabvumidza mushonga mutsva we sevabertinib wekurapa varwere vakuru vane kenza yemapapu isina kubatwa munharaunda kana kuti inopararira isina masero madiki (NSCLC) ine HER2 (ERBB2) activating mutat...Verenga zvakawanda»

Varwere Vepasi Pose, Kana imi kana vadikanwi venyu muri kurwisa kenza uye muchitsvaga nzira dzekurapa dzakapfava uye dzinoshanda, tinoda kukuzivisai nezve tekinoroji itsva yekenza — Ultrasound Tissue Fragmentation Therapy. Kurapa uku kwepamusoro kwakabudirira...Verenga zvakawanda»

Kana kenza ikaisa mumvuri pahupenyu, sarudzo yega yega yekurapa ine zvazvinoreva zvikuru pahunhu uye chiremerera chehupenyu ihwohwo. Kune varwere vakwegura, vane mashandiro asina kunaka emwoyo nemapapu, vasingakwanise kushivirira kuvhiyiwa kana kuti anesthesia, kana kutsvaga nzira iri nani yekurwisa bundu, ...Verenga zvakawanda»

Musi wa31 Kurume, 2026, Center for Drug Evaluation of China's National Medical Products Administration yakapa nhau dzinonakidza: GFH375, yakagadzirwa neGenFleet Therapeutics, yave pamutemo kuiswa muchirongwa che "Breakthrough Therapy" chekurapa varwere vane chirwere chepancreatic chakapararira...Verenga zvakawanda»

Kune varwere vazhinji vekenza vakwegura nemhuri dzavo, kuongororwa kunowanzo konzerwa nekuora mwoyo. Kunyanya kana munhu akatarisana ne "mambo wekenza" - kenza yepancreatic - kurwadziwa kunorwadza uye kusakwanisa kudya zvinowanzobvisa chiremera chevarwere, zvichisiya vadikanwi vavo vachishungurudzika zvikuru. Ku...Verenga zvakawanda»

Musi wa24 Kurume, 2024, Center for Drug Evaluation yeChina's National Medical Products Administration yakazivisa kuti mushonga mutsva weTeclistamab unotarisirwa kusarudzwa semushonga unobudirira wekurapa varwere vakuru vane mishonga inodzokera shure kana isingashande zvakanaka...Verenga zvakawanda»

Munguva pfupi yapfuura, National Medical Products Administration (NMPA) yakabvumidza chiratidzo chitsva che antibody-drug conjugate (ADC) Disitamab vedotin yekurapa varwere vakuru vane kenza yemazamu isina kubviswa kana metastatic HER2-low expression (IHC 1+ kana IHC 2+/ISH-) uye metastases yechiropa, avo ...Verenga zvakawanda»

Musi wa10 Kurume, 2026, mushonga mutsva weB7-H3-targeting antibody-drug conjugate (ADC) YL201 wekubaiwa jekiseni, wakagadzirwa neMediLink Therapeutics, wakapihwa basa reBreakthrough Therapy Designation neCenter for Drug Evaluation of China's National Medical Products Administration. Chiratidzo chakapihwa...Verenga zvakawanda»

Munguva pfupi yapfuura, Center for Drug Evaluation (CDE) yeChina National Medical Products Administration yakabvumidza zviri pamutemo jekiseni reKSD-101, rakagadzirwa naKousai, kuti ripinde mumiedzo yekiriniki. Izvi hazvisi chete chiratidzo chekutanga chekudzivirira dendritic cell vaccine (DC vaccine) muChina kugamuchira FDA IND app...Verenga zvakawanda»